Catalyst Wire Dossier Catalyst Wire Dossier

rhEGF

recombinant human epidermal growth factor · Daewoong Pharmaceutical Co. LTD.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for rhEGF, covering 2014-08-04 to 2023-06-15. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer. [Phase 3]

See pricing